�Javelin Pharmaceuticals, Inc. (AMEX:JAV), a leading developer of novel products for pain management, is presenting data today on its PMI-150 drug nominee (intranasal ketalar for acute pain) at the Department of Defense's (DoD) 2008 Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference.
Javelin will present two posters, the number one, "The Pharmacokinetics, Safety, and Tolerability of Repeat Doses of Intranasal Ketamine in Healthy Volunteers," presents the pharmacokinetic results following recurrent intranasal
